Other Species / Isoforms
  SEC61B (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
P2-n-ub
______MpGPtPsGt
0 1
SEC61B (human) ______MpGPtPsGt P2-n-ub
SEC61B (mouse) ______MPGPtPsGt P2
SEC61B (rat) ______MPGPTPSAT P2
SEC61B (dog) ______MPGPTPSGT P2
T5-p
___MpGPtPsGtNVG
0 9
SEC61B (human) ___MpGPtPsGtNVG T5-p
SEC61B (mouse) ___MPGPtPsGtNVG T5-p
SEC61B (rat) ___MPGPTPSATNVG T5
SEC61B (dog) ___MPGPTPSGTNVG T5
S7-p
_MpGPtPsGtNVGss
0 10
SEC61B (human) _MpGPtPsGtNVGss S7-p
SEC61B (mouse) _MPGPtPsGtNVGss S7-p
SEC61B (rat) _MPGPTPSATNVGss S7
SEC61B (dog) _MPGPTPSGTNVGSS S7
T9-p
pGPtPsGtNVGssGR
Upstream
0 5
Regulatory protein:
  • TBK1 (human)
SEC61B (human) pGPtPsGtNVGssGR T9-p
SEC61B (mouse) PGPtPsGtNVGssGR T9-p
SEC61B (rat) PGPTPSATNVGssGR T9
SEC61B (dog) PGPTPSGTNVGSSGR T9
S13-p
PsGtNVGssGRsPsk
Upstream
0 18
Treatment
  • MG132_withdrawal
SEC61B (human) PsGtNVGssGRsPsk S13-p
SEC61B (mouse) PsGtNVGssGRsPsK S13-p
SEC61B (rat) PSATNVGssGRsPSK S13-p
SEC61B (dog) PSGTNVGSSGRSPSK S13
S14-p
sGtNVGssGRsPskA
0 20
SEC61B (human) sGtNVGssGRsPskA S14-p
SEC61B (mouse) sGtNVGssGRsPsKA S14-p
SEC61B (rat) SATNVGssGRsPSKA S14-p
SEC61B (dog) SGTNVGSSGRSPSKA S14
S17-p
NVGssGRsPskAVAA
Upstream
0 63
Regulatory protein:
  • TBK1 (human)
Treatment
  • metastatic potential
  • MG132_withdrawal
  • nocodazole
SEC61B (human) NVGssGRsPskAVAA S17-p
SEC61B (mouse) NVGssGRsPsKAVAA S17-p
SEC61B (rat) NVGssGRsPSKAVAA S17-p
SEC61B (dog) NVGSSGRSPSKAVAA S17
S19-p
GssGRsPskAVAARA
Upstream
0 20
Treatment
  • metastatic potential
  • MG132_withdrawal
  • nocodazole
SEC61B (human) GssGRsPskAVAARA S19-p
SEC61B (mouse) GssGRsPsKAVAARA S19-p
SEC61B (rat) GssGRsPSKAVAARA S19
SEC61B (dog) GSSGRSPSKAVAARA S19
K20-ub
ssGRsPskAVAARAA
0 1
SEC61B (human) ssGRsPskAVAARAA K20-ub
SEC61B (mouse) ssGRsPsKAVAARAA K20
SEC61B (rat) ssGRsPSKAVAARAA K20
SEC61B (dog) SSGRSPSKAVAARAA K20
S29-p
VAARAAGstVRQRKN
0 6
SEC61B (human) VAARAAGstVRQRKN S29-p
SEC61B (mouse) VAARAAGsTVRQRKN S29-p
SEC61B (rat) VAARAAGSTVRQRKN S29
SEC61B (dog) VAARAAGSTVRQRKN S29
T30-p
AARAAGstVRQRKNA
0 5
SEC61B (human) AARAAGstVRQRKNA T30-p
SEC61B (mouse) AARAAGsTVRQRKNA T30
SEC61B (rat) AARAAGSTVRQRKNA T30
SEC61B (dog) AARAAGSTVRQRKNA T30
S38-p
VRQRKNAsCGTRsAG
0 2
SEC61B (human) VRQRKNAsCGTRsAG S38-p
SEC61B (mouse) VRQRKNAsCGTRSAG S38-p
SEC61B (rat) VRQRKNASCGTRSAG S38
SEC61B (dog) VRQRKNASCGTRSAG S38
S43-p
NAsCGTRsAGRTTsA
0 1
SEC61B (human) NAsCGTRsAGRTTsA S43-p
SEC61B (mouse) NAsCGTRSAGRTtsA S43
SEC61B (rat) NASCGTRSAGRTTsA S43
SEC61B (dog) NASCGTRSAGRTTSA S43
T48
TRsAGRTTsAGtGGM
0 1
SEC61B (human) TRsAGRTTsAGtGGM T48
SEC61B (mouse) TRSAGRTtsAGtGGM T48-p
SEC61B (rat) TRSAGRTTsAGTGGM T48
SEC61B (dog) TRSAGRTTSAGTGGM T48
S49-p
RsAGRTTsAGtGGMW
Upstream
0 19
Treatment
  • metastatic potential
SEC61B (human) RsAGRTTsAGtGGMW S49-p
SEC61B (mouse) RSAGRTtsAGtGGMW S49-p
SEC61B (rat) RSAGRTTsAGTGGMW S49-p
SEC61B (dog) RSAGRTTSAGTGGMW S49
T52-p
GRTTsAGtGGMWRFY
0 2
SEC61B (human) GRTTsAGtGGMWRFY T52-p
SEC61B (mouse) GRTtsAGtGGMWRFY T52-p
SEC61B (rat) GRTTsAGTGGMWRFY T52
SEC61B (dog) GRTTSAGTGGMWRFY T52
T60-p
GGMWRFYtEDsPGLK
0 1
SEC61B (human) GGMWRFYtEDsPGLK T60-p
SEC61B (mouse) GGMWRFYTEDSPGLK T60
SEC61B (rat) GGMWRFYTEDSPGLK T60
SEC61B (dog) GGMWRFYTEDSPGLK T60
S63-p
WRFYtEDsPGLKVGP
0 1
SEC61B (human) WRFYtEDsPGLKVGP S63-p
SEC61B (mouse) WRFYTEDSPGLKVGP S63
SEC61B (rat) WRFYTEDSPGLKVGP S63
SEC61B (dog) WRFYTEDSPGLKVGP S63